Assessments
bleeding, thrombotic, Bleeding, thrombosis-related, bleeding-
ADVERSE EVENTS, BLEEDING, BLEEDING, EVENTS
The percentage of responders (patients with PLT ≥ 50 × 10For safety assessments, AEs (adverse events) and AEs of special interest (bleeding- and thrombosis-related AEs) were evaluated. The WHO Bleeding Scale at these time points: in the period of screening; during randomization; day 8; 3–10 days post-procedure; and day 35 (premature termination or at stopping the study drug) was employed to assess the bleeding severity. Furthermore, the protocol also was inclusive of imaging assessments such as ultrasonography, Doppler ultrasonography, computed tomography, or magnetic resonance imaging to score thrombotic events during screening, 6 ± 3 days following the invasive procedure, and premature termination or at stopping the drug under study.